1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Shire pipeline 'to add $3bn in sales by 2020'

 
• By Sukaina Virji

Shire says drug candidates in its pipeline will contribute $3bn in sales by 2020. The company set out its wares at an R&D day in New York eight weeks after AbbVie pulled out of a $53bn offer for the rare disease specialist following the US Treasury's tightening of tax rules (scripintelligence.com, 16 October 2014).

Shire says drug candidates in its pipeline will contribute $3bn in sales by 2020. The company set out its wares at an R&D day in New York eight weeks after AbbVie pulled out of a $53bn offer for the rare disease specialist following the US Treasury's tightening of tax rules (scripintelligence.com, 16 October 2014).

"Shire's clear and focused strategy has enabled us to transform our pipeline with 22 programs in the clinic, the most...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 
• By Sushmita Panda

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.

Vor Unveils Positive IgAN Data For Telitacicept, But Prioritizes gMG, Sjögren’s

 
• By Alaric DeArment

A China-only Phase III study for the anti-BAFF/APRIL fusion protein marks the latest positive dataset for the drug, which Vor licensed from China-based RemeGen in June.